Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1307-1313

  Fukushima, Masakazu ^a   Sakamoto, Kazuki ^a   Sakata, Minoru ^a   Nakagawa, Fumio ^a   Saito, Hitoshi ^a   Sakata, Yu ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b Misawa City Hospital   (Japan)

Author keywords

5 FU; CDDP; Chemoradiotherapy; Gimeracil; S 1; X ray

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; GIMERACIL; HISTONE H2AX; UFT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; WESTERN BLOTTING; X IRRADIATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; OXONIC ACID; PYRIDINES; RADIATION-SENSITIZING AGENTS; TEGAFUR; WHOLE-BODY IRRADIATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78149320175     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000987     Document Type: Article

References (31)

1. Tannock IF: Treatment of cancer with radiation and drugs. J Clin Oncol 14: 3156-3174, 1996.
2. Vokes EE and Weichselbaum RR: Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8: 911-934, 1990.
3. Belka C, Nieder C and Molls M: Biological basis of combine radio- and chemotherapy. In: Multimodal Concepts for Cytotoxic Drugs and Radiation Therapy. Brown JM, Metha MP and Mieder C (eds). Springer, Berlin, pp3-17, 2006.
4. Milas L, Mason KA, Liao Z and Ang KK: Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 25: 152-167, 2003. (Pubitemid 36133895)
5. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper V, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone. New Eng J Med 326: 1593-1598, 1992.
6. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeiner WJ, Hars V, George SL, Huang AT and Prosnitz LR: Hyper-fractionated irradiation with or without concurrent radiotherapy for locally advanced head and neck cancer. New Eng J Med 338: 1798-1804, 1998.
7. Furuse K, Fukuoka M and Kawahara M: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
8. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. New Eng J Med 340: 1137-1143, 1999.
9. Rich TA, Shepard RC and Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22: 2214-2232, 2004.
10. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C and Schalhorn A: Simultaneous radiochemothrapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16: 1318-1324, 1998.
11. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L and Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophargeal cancer: an intergroup study. J Clin Oncol 15: 277-284, 1997. (Pubitemid 27020584)
12. Walsh TN, Nooman N, Hollywood D, Kelly A, Keeling N and Hennessy TPJ: A comparison of multimodal therapy and surgery for esophargeal adenocarcinoma. New Eng J Med 335: 462-467, 1996.
13. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N and Novak JW: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 56: 2563-2568, 1981.
14. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M and Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. New Eng J Med 350: 1713-1721, 2004.
15. Ichinose Y, Nakai Y, Kudoh S, Senba H, Yoshida S, Nukiwa T, Yamamoto H, Yamane Y, Niitani H and UP-RT Study Group: Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10: 4369-4373, 2004. (Pubitemid 38878876)
16. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
17. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity on 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.
18. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H and S-1 Cooperative Study Group (Lung Cancer Working Group): Phase II study of S-1, a novel oral fluorouracil, in advanced non-small cell lung cancer. Br J Cancer 85: 939-943, 2001.
19. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M and Niitani H: S-1 plus cisplatin combination chemotherapy inpatients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10: 7860-7864, 2004.
20. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61: 615-621, 2008.
21. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H and Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94: 1575-1579, 2006.
22. Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H and Sato M: Combined effects of the oral fluoropyrimidine anti-cancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 40: 713-719, 2004.
23. Harada K, Kawaguchi S, Supriatno, Kawashima Y, Yoshida H and Sato M: S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett 226: 161-168, 2005.
24. Nakata E, Fukushima M, Takai Y, Nemoto K, Ogawa Y, Nomiya T, Nakamura Y, Milas L and Yamada S: S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. Oncol Rep 16: 465-471, 2006.
25. Zeng L, Ou G, Itasaka S, Harada H, Xie X, Shibuya K, Kizaka-Kondoh S, Morinibu A, Shinomiya K and Hiraoka M: TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 99: 2327-2335, 2008.
26. Kim HM, Bang S, Park JY, Seong J, Song SY, Cheng JB and Park SW: Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol 63: 535-541, 2009.
27. Tsukuda M, Ishitoya J, Mikami Y, Matsuda C, Horiuchi C, Taguchi T, Satake K, Kawano T, Takahashi M, Nishimura G, Kawakami M, Sakuma Y, Watanabe M, Shiono O, Komatsu M and Yamashita Y: Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64: 945-952, 2009.
28. Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM and Sebolt-Leopold JS: Dihydroisoquinolines: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des 7: 107-117, 1991.
29. Banasik M, Komura H, Shimoyama M and Ueda K: Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl) transferase. J Biol Chem 267: 1569-1575, 1992.
30. Griffin RJ, Pemberton LC, Rhodes D, Bleasdale C, Bowman K, Calvert AH, Curtin NJ, Durkacz BW, Newell DR and Porteous JK: Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). Anticancer Drug Des 10: 507-514, 1995.
31. Nishimura Y: Rationale for chemoradiotherapy. Int J Clin Oncol 9: 414-420, 2004.